广泛期小细胞肺癌单纯脑进展后原方案续用联合脑放疗更优
这项多中心队列研究筛查889例ES-SCLC患者,203例出现单纯脑进展后分为三组:原方案全身治疗联合脑放疗(OTP+BRT)、换用方案联合脑放疗(ST+BRT)或单独换用方案(ST)。OTP+BRT组中位OS2达14.7个月,显著优于ST组10.2个月和ST+BRT组9.8个月,且第二线PFS也改善。
要点
- ES-SCLC单纯脑进展后,续用原方案联合脑放疗较换药方案显著改善生存。
- OTP+BRT组中位OS2为14.7个月,ST组10.2个月(HR 1.68),ST+BRT组9.8个月(HR 1.67)。
核心结论
- ES-SCLC患者出现单纯脑进展后,续用原全身治疗方案联合脑放疗较换用全身治疗方案可显著改善生存。
研究设计与样本
- 多中心队列研究,筛查889例ES-SCLC患者,203例出现单纯脑进展纳入分析。
主要发现
- 多变量分析证实OTP+BRT是改善生存的独立预后因素。
- 获益在既往接受免疫治疗和初始PFS较长(≥7.5个月)的患者中最为明显。
- 不同放疗模式(全脑放疗 vs 立体定向放射外科)之间未观察到显著生存差异。
临床怎么用
- 对于一线治疗后单纯脑进展的ES-SCLC患者,可考虑续用原全身治疗方案联合脑放疗,而非换用全身治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal second-line strategy for patients with extensive-stage small cell lung cancer (ES-SCLC) developing brain-only progression (BOP) after first-line therapy remains undefined. We aimed to evaluate the efficacy of continuing the original systemic therapy versus switching strategies. METHODS: This multicenter cohort study screened 889 patients with ES-SCLC. A total of 203 patients developing BOP were assigned to 3 second-line strategies: continuation of original systemic therapy plus brain radiotherapy (OTP + BRT), substitution therapy plus BRT (ST + BRT), or substitution therapy alone (ST). Inverse probability of treatment weighting was used to balance baseline characteristics. The primary end point was overall survival from second-line initiation (OS2). RESULTS: In the inverse probability of treatment weighting-weighted analysis of 203 BOP patients, OTP + BRT demonstrated significantly superior median OS2 (14.7 months) compared with ST (10.2 months; hazard ratio [HR], 1.68; P = .028) and ST + BRT (9.8 months; HR, 1.67; P = .023). OTP + BRT also yielded improved median second-line progression-free survival (PFS) (8.0 months) versus ST (4.0 months; P = .024). Multivariable analysis confirmed OTP + BRT as an independent prognostic factor for improved survival. The benefit was most pronounced in patients with prior immunotherapy and longer initial PFS (≥7.5 months). No significant survival differences were observed among radiotherapy modalities (whole-brain radiotherapy v stereotactic radiosurgery). CONCLUSION: For ES-SCLC patients with BOP, continuing the original systemic regimen plus BRT yields superior survival compared with switching systemic therapy. This supports a site-of-progression-directed strategy, effectively controlling the CNS sanctuary while maintaining an effective systemic backbone.
引用
- Lu S, Jia J, Ren K, et al. Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment. J Clin Oncol. 2026. PMID: 42133905. doi:10.1200/JCO-25-02536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。